alpha-Tocopherol enhances tumour growth inhibition by cis-dichlorodiammine platinum (II)

• Published in: Brazilian journal of medical and biological research 2000-08, Vol.33 (8), p.929-936
• Main Authors: Sarna, S, Kumar, A, Bhola, R K
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; BIOLOGY; Case-Control Studies; cisplatin; Cisplatin - therapeutic use; Dalton's lymphoma; Disease-Free Survival; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Male; MEDICINE, RESEARCH & EXPERIMENTAL; Mice; Neoplasms, Experimental - drug therapy; Tumor Cells, Cultured; tumour growth inhibition; vitamin E; Vitamin E - pharmacology; Vitamin E - therapeutic use
• ISSN: 0100-879X; 1414-431X; 0100-879X; 1414-431X
• DOI: 10.1590/S0100-879X2000000800009

Present studies indicate that alpha-tocopherol enhances the efficacy of cisplatin as demonstrated by inoculation of Dalton's lymphoma cells incubated with either cisplatin (5 or 10 microg/ml) alone or cisplatin + alpha-tocopherol (25 or 50 microg/ml) into C3H/He mice. Tumour cells (3 x 10(6) cells/mouse) incubated with cisplatin grow slowly in syngeneic mice as indicated by the late appearance of tumour. However, mice failed to develop tumour when inoculated with tumour cells incubated with cisplatin + alpha-tocopherol. When the animals were challenged with tumour cells (3 x 10(6) cells/mouse) on the 15th day after the initial inoculation, 30-50% survived more than 60 days, with 10% tumour-free survivors being observed in some groups. Antitumour activity was higher in mice receiving lymphoma cells (3 x 10(6) cells/mouse) preincubated with cisplatin + alpha-tocopherol compared to cisplatin alone. Tumour-bearing mice receiving cisplatin in combination with different concentrations of alpha-tocopherol exhibited significantly higher (P